Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATGross ProfitLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Vivos Therapeutics (VVOS) Loans and Notes Receivables (2019 - 2021)

Vivos Therapeutics has reported Loans and Notes Receivables over the past 3 years, most recently at $61864.0 for Q3 2021.

  • Quarterly Loans and Notes Receivables changed N/A to $61864.0 in Q3 2021 from the year-ago period, while the trailing twelve-month figure was $61864.0 through Sep 2021, changed N/A year-over-year, with the annual reading at $84000.0 for FY2020, 0.82% down from the prior year.
  • Loans and Notes Receivables was $61864.0 for Q3 2021 at Vivos Therapeutics, up from $56732.0 in the prior quarter.
  • Over five years, Loans and Notes Receivables peaked at $84696.0 in Q4 2019 and troughed at $56732.0 in Q2 2021.
  • The 3-year median for Loans and Notes Receivables is $84000.0 (2020), against an average of $74397.6.
  • The largest YoY upside for Loans and Notes Receivables was 0.82% in 2020 against a maximum downside of 0.82% in 2020.
  • A 3-year view of Loans and Notes Receivables shows it stood at $84696.0 in 2019, then dropped by 0.82% to $84000.0 in 2020, then decreased by 26.35% to $61864.0 in 2021.
  • Per Business Quant, the three most recent readings for VVOS's Loans and Notes Receivables are $61864.0 (Q3 2021), $56732.0 (Q2 2021), and $84696.0 (Q1 2021).